Aptinyx Inc (APTX) Expected to Announce Quarterly Sales of $1.10 Million
Equities analysts expect Aptinyx Inc (NASDAQ:APTX) to post $1.10 million in sales for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided estimates for Aptinyx’s earnings, with the highest sales estimate coming in at $1.20 million and the lowest estimate coming in at $1.00 million. The company is expected to issue its next earnings results on Tuesday, November 13th.
According to Zacks, analysts expect that Aptinyx will report full year sales of $6.50 million for the current financial year, with estimates ranging from $6.00 million to $6.99 million. For the next financial year, analysts anticipate that the firm will post sales of $4.00 million per share. Zacks’ sales calculations are a mean average based on a survey of research analysts that follow Aptinyx.
Aptinyx (NASDAQ:APTX) last posted its quarterly earnings data on Tuesday, August 14th. The company reported ($1.83) EPS for the quarter, missing analysts’ consensus estimates of ($0.48) by ($1.35). The company had revenue of $2.13 million during the quarter, compared to the consensus estimate of $2.10 million.
In related news, CEO Norbert G. Riedel purchased 2,400 shares of Aptinyx stock in a transaction on Monday, June 25th. The stock was acquired at an average price of $16.00 per share, for a total transaction of $38,400.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Adam Koppel purchased 400,000 shares of Aptinyx stock in a transaction on Monday, June 25th. The stock was bought at an average price of $16.00 per share, with a total value of $6,400,000.00. The disclosure for this purchase can be found here. In the last quarter, insiders have purchased 566,900 shares of company stock valued at $9,070,400.
Large investors have recently added to or reduced their stakes in the stock. Point72 Hong Kong Ltd bought a new stake in shares of Aptinyx in the 2nd quarter valued at approximately $134,000. Birchview Capital LP purchased a new position in Aptinyx during the 2nd quarter worth $242,000. TD Asset Management Inc. purchased a new position in Aptinyx during the 2nd quarter worth $253,000. Mutual of America Capital Management LLC purchased a new position in shares of Aptinyx in the 2nd quarter valued at $457,000. Finally, Cowen Inc. purchased a new position in shares of Aptinyx in the 2nd quarter valued at $546,000. Hedge funds and other institutional investors own 60.05% of the company’s stock.
Aptinyx stock traded up $0.21 during mid-day trading on Friday, reaching $30.15. 81,900 shares of the stock traded hands, compared to its average volume of 122,288. Aptinyx has a 12-month low of $17.35 and a 12-month high of $32.25.
Aptinyx Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. It is developing NYX-2925 that is in Phase II clinical trial for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II exploratory clinical trial for fibromyalgia; and NYX-783, an NMDAr receptor that is in Phase I clinical trial for the treatment of post-traumatic stress disorder.
Further Reading: Growth Stocks, What They Are, What They Are Not
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aptinyx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptinyx and related companies with MarketBeat.com's FREE daily email newsletter.